Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers

2022; Elsevier BV; Volume: 29; Issue: 1 Linguagem: Inglês

10.1016/j.cmi.2022.07.006

ISSN

1469-0691

Autores

Rosa Polo, Xabier García‐Albéniz, Carolina Terán, Miguel Morales, David Rial‐Crestelo, María Ángeles Garcinuño, Miguel García Deltoro, César Hita, Juan Luís Gómez-Sirvent, L Buzón, Alberto Díaz de Santiago, Jose Pérez Arellano, Jesús Sanz, P Bachiller, S. Martínez, Vicens Díaz-Brito, Mar Masiá, Alicia Hernández‐Torres, María José Guerra Palmero, Jesús Santos, Piedad Arazo, Leopoldo Muñoz, José Ramón Arribas, Pablo M. De Salazar, Santiago Moreno, Miguel A. Hernán, Julia del Amo, Julia del Amo, Rosa Polo, Santiago Moreno, Juan Berenguer, Estebán Martínez, Miguel A. Hernán, Pablo M. De Salazar, Xabier García‐Albéniz,

Tópico(s)

Long-Term Effects of COVID-19

Resumo

To assess the effect of hydroxychloroquine (HCQ) and Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) as pre-exposure prophylaxis on COVID-19 risk.

Referência(s)